Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure César O. Freytes, Mei-Jie Zhang,

Slides:

Advertisements

Similar presentations

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Advertisements

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Timothy S.

Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.

Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma Baldeep Wirk, Timothy S. Fenske,

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates Ian Nivison-Smith, Judy M. Simpson, Anthony.

Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report.

Nonmyeloablative conditioning for relapsed follicular lymphoma

Superior Survival after Autologous vs

Allogeneic Bone Marrow Transplantation for Low-Grade Lymphoma

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular.

Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma Ravi Vij, Shaji Kumar, Mei-Jie Zhang,

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma Dan T. Vogl, Tao Wang, Waleska S. Pérez,

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents Thomas G. Gross, Gregory A. Hale,

Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age Years with Acute Myelogenous Leukemia in First.

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome Philippe Armand,

Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma Navneet S. Majhail, Daniel J. Weisdorf,

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Marcelo C. Pasquini, Mei-Jie Zhang, Bruno C

Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR Gregory.

Outcome of Transplantation for Myelofibrosis

Betty T. Tran, Abigail Halperin, Jason W. Chien

Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma Marcel P. Devetten,

Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission Julie M Vose, Douglas J Rizzo, Jing Tao-Wu,

Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma Robert Chen, Joycelynne.

A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing.

Biology of Blood and Marrow Transplantation

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic.

Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival Brian L. McClune, Kwang Woo Ahn, Hai-Lin.

Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International.

Manish Sharma, Mei-Jie Zhang, Xiaobo Zhong, Muneer H

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting.

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International.

Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation Shaji Kumar, Waleska S. Pérez, Mei-Jie.

High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma Lisa Y. Law,

Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and.

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International.

Jeffrey Schriber, Manza-A. Agovi, Vincent Ho, Karen K

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Risk Factors Affecting Outcome of Second HLA-Matched Sibling Donor Transplantations for Graft Failure in Severe Acquired Aplastic Anemia John T. Horan,

Parameswaran N. Hari, Navneet S

Athanasios Anagnostopoulos, Parameswaran N. Hari, Waleska S

Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched.

Blood and Marrow Transplant Handbook

IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation:

Koen van Besien, Jeanette Carreras, Philip J. Bierman, Brent R

Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma Tanya M. Wildes, Kristan M. Augustin, Diane.

Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study Luis F.

Patrick J. Stiff, Manza-A. Agovi, Karen H

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning.

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma∗ Theresa Hahn, Philip L. McCarthy,

Salvage Second Hematopoietic Cell Transplantation in Myeloma

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Presentation transcript:

Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure César O. Freytes, Mei-Jie Zhang, Jeanette Carreras, Linda J. Burns, Robert Peter Gale, Luis Isola, Miguel-Angel Perales, Matthew Seftel, Julie M. Vose, Alan M. Miller, John Gibson, Thomas G. Gross, Philip A. Rowlings, David J. Inwards, Santiago Pavlovsky, Rodrigo Martino, David I. Marks, Gregory A. Hale, Sonali M. Smith, Harry C. Schouten, Simon Slavin, Thomas R. Klumpp, Hillard M. Lazarus, Koen van Besien, Parameswaran N. Hari Biology of Blood and Marrow Transplantation Volume 18, Issue 8, Pages 1255-1264 (August 2012) DOI: 10.1016/j.bbmt.2011.12.581 Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 (A) Cumulative incidence of NRM and disease progression after RIC/NST in patients who relapsed after auto-HSCT for NHL. (B) Probabilities of PFS and OS after RIC/NST in patients who relapsed after auto-HSCT for NHL. Biology of Blood and Marrow Transplantation 2012 18, 1255-1264DOI: (10.1016/j.bbmt.2011.12.581) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Probability of PFS after RIC/NST in patients who relapsed after auto-HSCT for NHL, according to histology at the time of RIC/NST. Biology of Blood and Marrow Transplantation 2012 18, 1255-1264DOI: (10.1016/j.bbmt.2011.12.581) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Probability of NRM after RIC/NST according to KPS in patients who relapsed after auto-HSCT for NHL. Biology of Blood and Marrow Transplantation 2012 18, 1255-1264DOI: (10.1016/j.bbmt.2011.12.581) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Probability of relapse after RIC/NST in patients who relapsed after auto-HSCT for NHL, according to the time interval between transplantations. Biology of Blood and Marrow Transplantation 2012 18, 1255-1264DOI: (10.1016/j.bbmt.2011.12.581) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Probability of PFS after RIC/NST in patients who relapsed after auto-HSCT for NHL according to KPS, interval between auto-HSCT and RIC/NST, use of TBI-containing conditioning regimen, and disease status at the time of RIC/NST. Biology of Blood and Marrow Transplantation 2012 18, 1255-1264DOI: (10.1016/j.bbmt.2011.12.581) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 6 Probability of PFS after RIC/NST in patients who relapsed after auto-HSCT for NHL according to conditioning regimen. Biology of Blood and Marrow Transplantation 2012 18, 1255-1264DOI: (10.1016/j.bbmt.2011.12.581) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions